Jessica Lynn has an educational background in writing and marketing. She firmly believes in the power of writing in amplifying voices, and looks forward to doing so for the rare disease community.

    ICYMI: SM-88 Receives Orphan Drug Designation as Pancreatic Cancer Treatment
    mohamed_hassan / Pixabay

    ICYMI: SM-88 Receives Orphan Drug Designation as Pancreatic Cancer Treatment

      Earlier this week, biotechnology company Time Technologies announced that its drug candidate SM-88 received Orphan Drug Designation from the FDA for the treatment of pancreatic cancer. The FDA defines…

    Continue Reading ICYMI: SM-88 Receives Orphan Drug Designation as Pancreatic Cancer Treatment
    Doctors Should Continue Assessing Patients for Tardive Dyskinesia During Pandemic
    Source: pixabay.com

    Doctors Should Continue Assessing Patients for Tardive Dyskinesia During Pandemic

      Because of COVID-19, many meetings and events have been moved online - but that does not mean the learning has stopped. During the virtual Psych Congress Elevate conference, which…

    Continue Reading Doctors Should Continue Assessing Patients for Tardive Dyskinesia During Pandemic
    Ripretinib for GIST Receives Priority Review Status in China
    mohamed_hassan / Pixabay

    Ripretinib for GIST Receives Priority Review Status in China

      According to ONCLive, ripretinib, designed to treat patients with advanced gastrointestinal stroll tumors (GIST), was given Priority Review status in China by the National Medical Products Administration. This status…

    Continue Reading Ripretinib for GIST Receives Priority Review Status in China
    Researchers Develop Potential Treatment for Best Disease
    source: pixabay.com

    Researchers Develop Potential Treatment for Best Disease

      Currently, over 200 different mutations are linked to the development of best vitelliform macular degeneration (BVMD, or Best disease). But while certain treatments may treat certain mutations, there has…

    Continue Reading Researchers Develop Potential Treatment for Best Disease
    Clinical Trial Results Show Rilzabrutinib as Effective Pemphigus Treatment
    stevepb / Pixabay

    Clinical Trial Results Show Rilzabrutinib as Effective Pemphigus Treatment

      Last month, at the American Academy of Dermatology (AAD) Virtual Annual Meeting, Dr. Dedee F. Murrell, MD, explained the efficacy of rilzabrutinib for treating pemphigus. According to MDedge, many…

    Continue Reading Clinical Trial Results Show Rilzabrutinib as Effective Pemphigus Treatment
    Phase 2 Trial Announced for Potential COVID-19 Treatment TXA127
    valelopardo / Pixabay

    Phase 2 Trial Announced for Potential COVID-19 Treatment TXA127

      As COVID-19 continues to spread, the rush for a treatment or cure continues. Today, on August 4, there are 18.2 million diagnosed cases worldwide, with an associated 692,000 deaths.…

    Continue Reading Phase 2 Trial Announced for Potential COVID-19 Treatment TXA127
    New Study Suggests Targeted Next Generation Sequencing Can Aid in Identification of Menkes Disease
    source: pixabay.com

    New Study Suggests Targeted Next Generation Sequencing Can Aid in Identification of Menkes Disease

      In a recent press release, biopharmaceutical company Fortress Biotech announced that their study regarding ATP7A targeted next generation DNA sequencing for Menkes disease was published in Molecular Genetics and Metabolism…

    Continue Reading New Study Suggests Targeted Next Generation Sequencing Can Aid in Identification of Menkes Disease
    Analyzing the Alzheimer’s Disease Proteome Develops New Drug Targets
    source: pixabay.com

    Analyzing the Alzheimer’s Disease Proteome Develops New Drug Targets

      As of right now, there are no treatments for Alzheimer's disease, a progressive neurodegenerative disorder. However, that may soon change. A study led by UCLA researchers identified potential drug…

    Continue Reading Analyzing the Alzheimer’s Disease Proteome Develops New Drug Targets
    FDA-Approved iOS App Coordinates Neuromodulation Therapies
    source: pixabay.com

    FDA-Approved iOS App Coordinates Neuromodulation Therapies

      According to Parkinson's News Today, the FDA recently approved an iOS app to assist patients with neurological disorders. Developed by Abbott, the Patient Controller App offers unique telemedicine at…

    Continue Reading FDA-Approved iOS App Coordinates Neuromodulation Therapies
    Wet Macular Degeneration: X-82 Clinical Trial Stopped Over Toxicity Issues
    Source: Pixabay.com

    Wet Macular Degeneration: X-82 Clinical Trial Stopped Over Toxicity Issues

      Over the last few days, the American Society of Retina Specialists (ASRS) held their Annual Virtual Meeting; coined "2020 Virtual Sessions," professionals converged online to share insights into ophthalmological…

    Continue Reading Wet Macular Degeneration: X-82 Clinical Trial Stopped Over Toxicity Issues
    Mike’s Story: Overcoming COVID-19 and Guillain-Barré Syndrome
    https://pixabay.com/en/cuba-oldtimer-old-car-forest-red-1197800/

    Mike’s Story: Overcoming COVID-19 and Guillain-Barré Syndrome

      When it comes to COVID-19, many people believe, "Well, it can't happen to me!" But with 16.8 million diagnosed cases worldwide, and nearly 4.5 million of those in the…

    Continue Reading Mike’s Story: Overcoming COVID-19 and Guillain-Barré Syndrome
    RGLS4326 Granted Orphan Drug Designation for Treatment of ADPKD
    Photo by Robina Weermeijer on Unsplash

    RGLS4326 Granted Orphan Drug Designation for Treatment of ADPKD

      In a recent press release, biopharmaceutical company Regulus Therapeutics, Inc. announced that their drug candidate, RGLS4326, received Orphan Drug Designation for the treatment of autosomal dominant polycystic kidney disease…

    Continue Reading RGLS4326 Granted Orphan Drug Designation for Treatment of ADPKD
    Close Menu